Dissecting negative regulation of Toll-like receptor signaling

Trends in Immunology

Volumn 33, Issue 9, 2012, Pages 449-458

  Kondo, Takeshi ^a,b   Kawai, Taro ^a,b   Akira, Shizuo ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; DAMAGE ASSOCIATED MOLECULAR PATTERN; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I; SIGNAL PEPTIDE; TIR ASSOCIATED PROTEIN; TIR DOMAIN CONTAINING ADAPTOR PROTEIN-INDUCING BETA INTERFERON; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2; TRAF FAMILYMEMBER IMMUNOGLOBULIN ENHANCER BINDING PROTEIN ACTIVATOR BINDING KINASE 1; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ASTHMA; ATHEROSCLEROSIS; CANDIDIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISSOCIATION; FLAVIVIRUS INFECTION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; MALARIA; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN PROCESSING; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCRIPTION REGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; GENE EXPRESSION REGULATION; HUMANS; PROTEIN BINDING; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TRANSCRIPTION, GENETIC;

EID: 84865298775     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.05.002     Document Type: Review

References (97)

1. Janeway C.A., Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002, 20:197-216.
2. Akira S., et al. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
3. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
4. Chen G.Y., Nunez G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 2010, 10:826-837.
5. Liew F.Y., et al. Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 2005, 5:446-458.
6. Palsson-McDermott E.M., et al. TAG, a splice variant of the adaptor TRAM, negatively regulates the adaptor MyD88-independent TLR4 pathway. Nat. Immunol. 2009, 10:579-586.
7. O'Neill L.A., Bowie A.G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 2007, 7:353-364.
8. Carty M., et al. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat. Immunol. 2006, 7:1074-1081.
9. Takaoka A., et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005, 434:243-249.
10. Negishi H., et al. Negative regulation of Toll-like-receptor signaling by IRF-4. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:15989-15994.
11. Sun H., et al. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell 2008, 133:415-426.
12. Chun H.J., et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 2002, 419:395-399.
13. Lemmers B., et al. Essential role for caspase-8 in Toll-like receptors and NFkappaB signaling. J. Biol. Chem. 2007, 282:7416-7423.
14. Davis B.K., et al. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu. Rev. Immunol. 2011, 29:707-735.
15. Xia X., et al. NLRX1 negatively regulates TLR-induced NF-kappaB signaling by targeting TRAF6 and IKK. Immunity 2011, 34:843-853.
16. Rebsamen M., et al. NLRX1/NOD5 deficiency does not affect MAVS signalling. Cell Death Differ. 2011, 18:1387.
17. Cui J., et al. NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways. Cell 2010, 141:483-496.
18. Kumar H., et al. NLRC5 deficiency does not influence cytokine induction by virus and bacteria infections. J. Immunol. 2010, 186:994-1000.
19. Kawagoe T., et al. TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. Nat. Immunol. 2009, 10:965-972.
20. Yuk J.M., et al. The orphan nuclear receptor SHP acts as a negative regulator in inflammatory signaling triggered by Toll-like receptors. Nat. Immunol. 2011, 12:742-751.
21. Ananieva O., et al. The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nat. Immunol. 2008, 9:1028-1036.
22. Ajibade A.A., et al. TAK1 negatively regulates NF-kappaB and p38 MAP kinase activation in Gr-1(+)CD11b(+) neutrophils. Immunity 2012, 36:43-54.
23. An H., et al. Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat. Immunol. 2008, 9:542-550.
24. Abu-Dayyeh I., et al. Leishmania-induced IRAK-1 inactivation is mediated by SHP-1 interacting with an evolutionarily conserved KTIM motif. PLoS Negl. Trop. Dis. 2008, 2:e305.
25. An H., et al. SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production. Immunity 2006, 25:919-928.
26. Turer E.E., et al. Homeostatic MyD88-dependent signals cause lethal inflammation in the absence of A20. J. Exp. Med. 2008, 205:451-464.
27. Skaug B., et al. Direct, noncatalytic mechanism of IKK inhibition by A20. Mol. Cell 2011, 44:559-571.
28. Yoshida H., et al. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J. Biol. Chem. 2005, 280:41111-41121.
29. Zhou F., et al. Ubiquitin-specific protease 4 mitigates Toll-like/interleukin-1 receptor signaling and regulates innate immune activation. J. Biol. Chem. 2012, 287:11002-11010.
30. Kayagaki N., et al. DUBA: a deubiquitinase that regulates type I interferon production. Science 2007, 318:1628-1632.
31. Jiang X., Chen Z.J. The role of ubiquitylation in immune defence and pathogen evasion. Nat. Rev. Immunol. 2011, 12:35-48.
32. Yoshimura A., et al. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 2007, 7:454-465.
33. Ivashkiv L.B. Cross-regulation of signaling by ITAM-associated receptors. Nat. Immunol. 2009, 10:340-347.
34. Wang L., et al. Indirect inhibition of Toll-like receptor and type I interferon responses by ITAM-coupled receptors and integrins. Immunity 2010, 32:518-530.
35. Han C., et al. Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nat. Immunol. 2010, 11:734-742.
36. Kagan J.C., Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 2006, 125:943-955.
37. Tanaka T., et al. PDLIM2-mediated termination of transcription factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 subunit. Nat. Immunol. 2007, 8:584-591.
38. Shi M., et al. TRIM30 alpha negatively regulates TLR-mediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation. Nat. Immunol. 2008, 9:369-377.
39. Zhao W., et al. E3 ubiquitin ligase tripartite motif 38 negatively regulates TLR-mediated immune responses by proteasomal degradation of TNF receptor-associated factor 6 in macrophages. J. Immunol. 2012, 188:2567-2574.
40. Saitoh T., et al. Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1. Nat. Immunol. 2006, 7:598-605.
41. Tun-Kyi A., et al. Essential role for the prolyl isomerase Pin1 in Toll-like receptor signaling and type I interferon-mediated immunity. Nat. Immunol. 2011, 12:733-741.
42. Yu Y., Hayward G.S. The ubiquitin E3 ligase RAUL negatively regulates type i interferon through ubiquitination of the transcription factors IRF7 and IRF3. Immunity 2010, 33:863-877.
43. Levine B., et al. Autophagy in immunity and inflammation. Nature 2011, 469:323-335.
44. Saitoh T., et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 2008, 456:264-268.
45. Cadwell K., et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 2008, 456:259-263.
46. Ramirez-Carrozzi V.R., et al. Selective and antagonistic functions of SWI/SNF and Mi-2beta nucleosome remodeling complexes during an inflammatory response. Genes Dev. 2006, 20:282-296.
47. Whitmore M.M., et al. Negative regulation of TLR-signaling pathways by activating transcription factor-3. J. Immunol. 2007, 179:3622-3630.
48. Kuwata H., et al. IkappaBNS inhibits induction of a subset of Toll-like receptor-dependent genes and limits inflammation. Immunity 2006, 24:41-51.
49. Carmody R.J., et al. Negative regulation of toll-like receptor signaling by NF-kappaB p50 ubiquitination blockade. Science 2007, 317:675-678.
50. Saijo K., et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009, 137:47-59.
51. Esser C., et al. The aryl hydrocarbon receptor in immunity. Trends Immunol. 2009, 30:447-454.
52. Kimura A., et al. Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J. Exp. Med. 2009, 206:2027-2035.
53. Carrick D.M., et al. The tandem CCCH zinc finger protein tristetraprolin and its relevance to cytokine mRNA turnover and arthritis. Arthritis Res. Ther. 2004, 6:248-264.
54. Matsushita K., et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 2009, 458:1185-1190.
55. Liang J., et al. MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-kappaB signaling. J. Exp. Med. 2010, 207:2959-2973.
56. Iwasaki H., et al. The IkappaB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1. Nat. Immunol. 2011, 12:1167-1175.
57. O'Neill L.A., et al. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat. Rev. Immunol. 2011, 11:163-175.
58. O'Connell R.M., et al. MicroRNA-155 is induced during the macrophage inflammatory response. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:1604-1609.
59. Huang R.S., et al. MicroRNA-155 silencing enhances inflammatory response and lipid uptake in oxidized low-density lipoprotein-stimulated human THP-1 macrophages. J. Investig. Med. 2010, 58:961-967.
60. Tang B., et al. Identification of MyD88 as a novel target of miR-155, involved in negative regulation of Helicobacter pylori-induced inflammation. FEBS Lett. 2010, 584:1481-1486.
61. Ceppi M., et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2735-2740.
62. Tili E., et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J. Immunol. 2007, 179:5082-5089.
63. Gottwein E., et al. A viral microRNA functions as an orthologue of cellular miR-155. Nature 2007, 450:1096-1099.
64. Thai T.H., et al. Regulation of the germinal center response by microRNA-155. Science 2007, 316:604-608.
65. Rodriguez A., et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007, 316:608-611.
66. O'Connell R.M., et al. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7113-7118.
67. Taganov K.D., et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:12481-12486.
68. Zhao J.L., et al. NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:9184-9189.
69. Chassin C., et al. miR-146a mediates protective innate immune tolerance in the neonate intestine. Cell Host Microbe 2010, 8:358-368.
70. Sheedy F.J., et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat. Immunol. 2010, 11:141-147.
71. Bowie A.G., Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat. Rev. Immunol. 2008, 8:911-922.
72. Li X.D., et al. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:17717-17722.
73. Stack J., et al. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med. 2005, 201:1007-1018.
74. Harte M.T., et al. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J. Exp. Med. 2003, 197:343-351.
75. Randow F., Lehner P.J. Viral avoidance and exploitation of the ubiquitin system. Nat. Cell Biol. 2009, 11:527-534.
76. Ashida H., et al. A bacterial E3 ubiquitin ligase IpaH9.8 targets NEMO/IKKgamma to dampen the host NF-kappaB-mediated inflammatory response. Nat. Cell Biol. 2010, 12:66-73.
77. Barry M., Fruh K. Viral modulators of cullin RING ubiquitin ligases: culling the host defense. Sci. STKE 2006, 2006:pe21.
78. Okumura A., et al. HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation. Virology 2008, 373:85-97.
79. Hajishengallis G., Lambris J.D. Microbial manipulation of receptor crosstalk in innate immunity. Nat. Rev. Immunol. 2011, 11:187-200.
80. Geijtenbeek T.B. Mycobacteria target DC-SIGN to suppress dendritic cell function. J. Exp. Med. 2003, 197:7-17.
81. Gringhuis S.I., et al. C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB. Immunity 2007, 26:605-616.
82. Gringhuis S.I., et al. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat. Immunol. 2009, 10:1081-1088.
83. O'Neill L.A. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat. Rev. Drug Discov. 2006, 5:549-563.
84. Kanzler H., et al. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 2007, 13:552-559.
85. Mullarkey M., et al. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 2003, 304:1093-1102.
86. Park B.S., et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009, 458:1191-1195.
87. Shimazu R., et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 1999, 189:1777-1782.
88. Ledeboer A., et al. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin. Investig. Drugs 2007, 16:935-950.
89. Barrat F.J., et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 2005, 202:1131-1139.
90. Rutz M., et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur. J. Immunol. 2004, 34:2541-2550.
91. Kuznik A., et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol. 2011, 186:4794-4804.
92. Macfarlane D.E., Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J. Immunol. 1998, 160:1122-1131.
93. Franklin B.S., et al. Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:3689-3694.
94. Barrat F.J., et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 2007, 37:3582-3586.
95. Davis C.N., et al. MyD88-dependent and -independent signaling by IL-1 in neurons probed by bifunctional Toll/IL-1 receptor domain/BB-loop mimetics. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:2953-2958.
96. Loiarro M., et al. Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J. Leukoc. Biol. 2007, 82:801-810.
97. Vereecke L., et al. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009, 30:383-391.